Description

The combination of Tamsulosin HCI – Finasteride is used for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia.

Tamsulosin

Drug class: Alpha blockers

• A selective alpha-1 adrenoceptor blocker, which blocks the adrenoceptors leading to the relaxation of smooth muscles in the bladder neck, and prostate to relax.

• Highly efficacious in patients with lower urinary tract symptoms due to benign prostatic enlargement.

• Considered as a safe and effective medical expulsive therapy choice for ureteral stones.

• Tamsulosin was better than placebo at improving international prostate symptom score (IPSS) and maximum flow rate (MFR).

• Blocks the effects of adrenalin on the muscle cells and causes the muscles to relax and thus resulting in a decrease in obstruction to the flow of urine.

• Beneficial in terms of the reduced number of ureteral colic episodes and the severity of pain in the patients.

Finasteride

Drug class:  5-alpha reductase inhibitors

• A competitive inhibitor of the 5-alpha reductase, an enzyme that converts testosterone to dihydrotestosterone (DHT).

• Conversion of testosterone to DHT by 5-alpha reductase is essential for prostatic hyperplasia.

• Inhibits prostatic enlargement by reducing circulating and intraprostatic dihydrotestosterone.

• Reduce the risk of the need for surgery including transurethral resection of the prostate (TURP) and prostatectomy.

• Substantially reduces the risk of incident clinical BPH in healthy older men.